UNK - PLATES: MATRIX ORBITAL

MAUDE Adverse Event Report

MAUDE data represents reports of adverse events involving medical devices. This maude entry was filed from a company representative,foreig report with the FDA on 2019-05-23 for UNK - PLATES: MATRIX ORBITAL manufactured by Oberdorf Synthes Produktions Gmbh.

Event Text Entries

[145984964] Brand name, common device name, procode, mfr, lot #, part #, udi #, 510k: this report is for an unknown synthes titanium mesh implant/unknown lot. Part and lot numbers are unknown; udi number is unknown. Device evaluated by mfr, manufacture date: without a lot number the device history records review could not be completed. Product was not returned. Based on the information available, it has been determined that no corrective and/or preventative action is proposed. This complaint will be accounted for and monitored via post market surveillance activities. If additional information is made available, the investigation will be updated as applicable. Device was used for treatment, not diagnosis. If information is obtained that was not available for the initial medwatch, a follow-up medwatch will be filed as appropriate. (b)(4).
Patient Sequence No: 1, Text Type: N, H10


[145984965] This report is being filed after the review of the following journal article: pedemonte, c. Et al. (2018), reconstruction of medial orbital wall using a retrocaruncular approach, journal of cranio-maxillo-facial surgery, vol. 46, pages 1726-1730 (chile). The purpose of this study is to analyze and describe the use of the retrocaruncular approach for the treatment of medial orbital wall fractures. During january 2011 and january 2017, a total of 30 patients underwent orbital reconstruction treatment with a retrocaruncular approach together with a transconjunctival extension and lateral canthotomy using an unknown synthes titanium mesh implant (matrixorbital). The minimum follow-up was 6 months. The following complications were reported as follows: 1 patient presented a delayed complication on the 5th day after the operation, developing a conjunctival granuloma on the caruncle of the affected eye socket. The granuloma was associated with a stitch to the inferior oblique muscle and was removed in an exploratory surgery without need to remove the mesh to resolve it. 1 patient developed delayed enophthalmos of the eye socket that was operated on after the 1st surgery, making a 2nd surgical intervention necessary to restore the lost orbital volume using customized implants. 1 patient, though unrelated to the type of approach used, developed post-traumatic glaucoma after 2 months. This is for an unknown synthes titanium mesh implant (matrixorbital). This is report 1 of 2 for (b)(4).
Patient Sequence No: 1, Text Type: D, B5


MAUDE Entry Details

Report Number8030965-2019-64435
MDR Report Key8636822
Report SourceCOMPANY REPRESENTATIVE,FOREIG
Date Received2019-05-23
Date of Report2019-04-24
Date Mfgr Received2019-06-21
Date Added to Maude2019-05-23
Event Key0
Report Source CodeManufacturer report
Manufacturer LinkY
Number of Patients in Event0
Adverse Event Flag3
Product Problem Flag3
Reprocessed and Reused Flag3
Reporter OccupationOTHER HEALTH CARE PROFESSIONAL
Health Professional3
Initial Report to FDA3
Report to FDA3
Event Location3
Manufacturer ContactKARA DITTY-BOVARD
Manufacturer Street1302 WRIGHTS LANE EAST
Manufacturer CityWEST CHESTER PA 19380
Manufacturer CountryUS
Manufacturer Postal19380
Manufacturer Phone6103142063
Single Use3
Previous Use Code3
Event Type3
Type of Report3

Device Details

Generic NameIMPLANT, ORBITAL, EXTRA-OCULAR
Product CodeHQX
Date Received2019-05-23
Catalog NumberUNK - PLATES: MATRIX ORBITAL
OperatorHEALTH PROFESSIONAL
Device AvailabilityN
Device AgeDA
Device Eval'ed by MfgrR
Device Sequence No1
Device Event Key0
ManufacturerOBERDORF SYNTHES PRODUKTIONS GMBH
Manufacturer AddressEIMATTSTRASSE 3 OBERDORF 4436 SZ 4436


Patients

Patient NumberTreatmentOutcomeDate
101. Required No Informationntervention 2019-05-23

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.